Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 To 55 Years of Age, inclusive) with Eosinophilic Esophagitis:A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Principal Investigator(s)
Email for information
Funded by
Geneva Foundation
Research Start Date
Status
Active
A double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of OBS treatment administered twice daily (qAM, pc and hs) for 12 weeks
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.